MOLOGEN and ONCOLOGIE: Global assignment and co-development agreement relating to MOLOGEN´s lead compound lefitolimod
(WorldNews Germany)

o Term sheet: Global assignment and co-development agreement for lead compound lefitolimod o Substantial potential payments in milestones and in addition royalties - near-term consideration of EUR23 million o Pivotal IMPALA study with lefitolimod would be almost entirely funded Berlin, 16 August 2018 - The biopharmaceutical company MOLOGEN AG yesterday signed, with the consent of the Supervisory Board, a term sheet outlining the framework for a global assignment of all intellectual property and other rights in MOLOGEN`s lead compound lefitolimod to ONCOLOGIE and an expansion of the existing global co-development agreement between MOLOGEN and ONCOLOGIE. The potential total deal value would be...